REGN:NGS-Regeneron Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 640.14

Change

+6.00 (+0.95)%

Market Cap

USD 42.08B

Volume

1.25M

Analyst Target

USD 674.63
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 123.21B
ARGX argenx NV ADR

N/A

USD 37.97B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 31.94B
ONC BeiGene, Ltd.

N/A

USD 28.70B
RPRX Royalty Pharma Plc

N/A

USD 19.31B
SMMT Summit Therapeutics PLC

N/A

USD 14.57B
UTHR United Therapeutics Corporatio..

N/A

USD 14.37B
INCY Incyte Corporation

N/A

USD 14.22B
MRNA Moderna Inc

N/A

USD 13.74B
INSM Insmed Inc

N/A

USD 13.70B

ETFs Containing REGN

EMEH:SW BNP Paribas Easy Energy &.. 8.55 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 8.30 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 8.28 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 7.52 % 0.00 %

N/A

USD 5.16M
IBB iShares Biotechnology ETF 7.05 % 0.47 %

N/A

USD 6.00B
BBH VanEck Biotech ETF 6.04 % 0.35 %

N/A

USD 0.40B
BIB ProShares Ultra Nasdaq Bi.. 5.24 % 0.95 %

N/A

USD 0.06B
SPQH:XETRA Global X S&P 500® Quarte.. 4.95 % 0.00 %

N/A

N/A
ZWHC:CA BMO Covered Call Health C.. 4.73 % 0.00 %

N/A

N/A
UBIO 4.54 % 0.95 %

N/A

N/A
EGUSAS:SW UBS (Irl) Fund Solutions .. 4.35 % 0.00 %

N/A

USD 0.10B
MEDX Horizon Kinetics Medical .. 4.26 % 0.00 %

N/A

N/A
BIS ProShares UltraShort Nasd.. 4.13 % 0.95 %

N/A

USD 3.28M
HEAL:CA 3.97 % 0.00 %

N/A

N/A
FDG American Century ETF Trus.. 3.60 % 0.00 %

N/A

N/A
CAPS:LSE First Trust Capital Stren.. 2.26 % 0.00 %

N/A

N/A
XLVE:CA 1.84 % 0.00 %

N/A

N/A
ACWV iShares MSCI Global Min V.. 0.00 % 0.20 %

N/A

USD 3.64B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FPX First Trust US Equity Opp.. 0.00 % 0.59 %

N/A

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.05B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
PXLG Invesco S&P 500 GARP ETF 0.00 % 0.39 %

N/A

N/A
IDNA iShares Genomics Immunolo.. 0.00 % 0.00 %

N/A

USD 0.12B
HERS-B:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
XMW:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

CAD 0.20B
XMY:CA iShares MSCI Min Vol Glob.. 0.00 % 0.48 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

N/A

N/A
HHL:CA Harvest Healthcare Leader.. 0.00 % 1.15 %

N/A

N/A
HERS:CA 0.00 % 0.62 %

N/A

N/A
FPX:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

N/A
SMRG:LSE 0.00 % 0.00 %

N/A

N/A
SMRU:LSE 0.00 % 0.00 %

N/A

N/A
VMOM:LSE 0.00 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
EMEH:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
GSDE:F BNP Paribas Easy Energy &.. 0.00 % 0.00 %

N/A

N/A
SM8T:F 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
BIOT 0.00 % 0.00 %

N/A

N/A
NVQ 0.00 % 0.00 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A
LYFE 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
XDNA:CA iShares Genomics Immunolo.. 0.00 % 0.00 %

N/A

CAD 5.00M

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.13% 62% D 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.13% 62% D 39% F
Trailing 12 Months  
Capital Gain -33.75% 60% D- 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.75% 60% D- 30% F
Trailing 5 Years  
Capital Gain 42.41% 78% C+ 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.41% 78% C+ 50% F
Average Annual (5 Year Horizon)  
Capital Gain 14.66% 63% D 69% C-
Dividend Return 14.66% 63% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.87% 97% N/A 80% B-
Risk Adjusted Return 77.69% 99% N/A 92% A
Market Capitalization 42.08B 100% F 99% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 60.10 32% 50%
Price/Book Ratio 2.60 41% 39%
Price / Cash Flow Ratio 17.28 4% 18%
Price/Free Cash Flow Ratio 13.18 6% 29%
Management Effectiveness  
Return on Equity 15.95% 96% 86%
Return on Invested Capital 12.22% 84% 78%
Return on Assets 7.31% 97% 90%
Debt to Equity Ratio 6.76% 64% 74%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.